1195795-81-3
Chemical Structure
BNN27
- CAS No.: 1195795-81-3
- Formula:C21H32O3
- Molecular Weight:332.48
InChIKey: FMOHTQBFGJULLE-YRWKUUEZSA-N
SMILES: C[C@@]12[C@]3(CC[C@@]1([H])[C@@]4([H])[C@]([C@@]5(C(C[C@H](CC5)O)=CC4)C)([H])CC2)[C@H](O3)CO
Biological Activity: BNN27 is a blood-brain barrier-penetrant, selective NGF receptor (TrkA and p75NTR) activator. BNN27 activates ERK1/2/AKT. BNN27 enhances NGF-induced differentiation/axonal growth and inhibits JNK after NGF withdrawal. BNN27 reduces Amyloid-β plaques, gliosis, and pro-inflammatory cytokines, and rescues synaptic/cholinergic deficits, neurogenesis, and working memory. BNN27 can be used in research on Alzheimer's disease, amyotrophic lateral sclerosis, diabetic retinopathy, inflammatory hyperalgesia, anxiety disorders, and multiple sclerosis[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BNN27 | 99.54% | BNN27 is a blood-brain barrier-penetrant, selective NGF receptor (TrkA and p75NTR) activator. BNN27 activates ERK1/2/AKT. BNN27 enhances NGF-induced differentiation/axonal growth and inhibits JNK after NGF withdrawal. BNN27 reduces Amyloid-β plaques, gliosis, and pro-inflammatory cytokines, and rescues synaptic/cholinergic deficits, neurogenesis, and working memory. BNN27 can be used in research on Alzheimer's disease, amyotrophic lateral sclerosis, diabetic retinopathy, inflammatory hyperalgesia, anxiety disorders, and multiple sclerosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kokkali M, et al. Multimodal beneficial effects of BNN27, a nerve growth factor synthetic mimetic, in the 5xFAD mouse model of Alzheimer’s disease. Molecular Psychiatry. 2025 Jun;30(6):2265-83.
- [2]. Bennett JP, et al. Pharmacological properties of microneurotrophin drugs developed for treatment of amyotrophic lateral sclerosis. Biochemical pharmacology. 2016 Oct 01;117:68-77.
- [3]. Pediaditakis I, et al. Selective and differential interactions of BNN27, a novel C17-spiroepoxy steroid derivative, with TrkA receptors, regulating neuronal survival and differentiation. Neuropharmacology. 2016 Dec;111:266-282.
- [4]. Ibán-Arias R, et al. Effect of topical administration of the microneurotrophin BNN27 in the diabetic rat retina. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2019 Nov;257(11):2429-2436.
- [5]. Kokras N, et al. Psychoactive properties of BNN27, a novel neurosteroid derivate, in male and female rats. Psychopharmacology. 2020 Aug;237(8):2435-2449. [Content Brief]
- [6]. Ibán-Arias R, et al. The Synthetic Microneurotrophin BNN27 Affects Retinal Function in Rats With Streptozotocin-Induced Diabetes. Diabetes. 2018 Feb;67(2):321-333.
- [7]. Poulaki S, et al. Analgesic and Anti-Inflammatory Effects of the Synthetic Neurosteroid Analogue BNN27 during CFA-Induced Hyperalgesia. Biomedicines. 2021 Sep 09;9(9):1185.
- [8]. Fragkiadaki E, et al. Effects of low doses of the novel dehydroepiandrosterone (DHEA) derivative BNN27 in rat models of anxiety. Psychopharmacology. 2024 Feb;241(2):341-350.
- [9]. Bonetto G, et al. The novel synthetic microneurotrophin BNN27 protects mature oligodendrocytes against cuprizone-induced death, through the NGF receptor TrkA. Glia. 2017 Aug;65(8):1376-1394.
